Stock Details
GRFS is Grifols, S.A.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 11.52$. Average daily volumn in 3 months 1.03M. Market cap 12.32B



Stock symbol : GRFS. Exchange : NasdaqGS. Currency : USD
Lastest price : 13.07$. Total volume : 703.58k. Market state POST
Click reload if you want to check the lastest price on market!!!

Grifols, S.A. (GRFS)
Last Price
13.07$
Change
-0.21
Volume
703.58k

Previous Close13.28
Open13.15
Day Range12.88-13.20
Bid12.60 x 1.8k
Ask14.50 x 1.8k
Volume703.58k
Average Volume1.03M
Market Cap12.32B
Beta0.17
52 Week Range10.10-19.07
Trailing P/E91.40
Foward P/E15.38
Dividend (Yield %)6.88%
Ex-Dividend Date2021-06-03



Financial Details


According to Grifols, S.A.'s financial reports the company's revenue in 2021 were 4.93B an decrease(-20%) over the years 2020 revenue that were of 5.34B. In 2021 the company's total earnings were 182.8M while total earnings in 2020 were 618.55M(-70.55%).


Loading ...



Organization

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting fa... ctors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumย–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoringย–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Market Cap:
12.32B
Revenue:
4.93B
Total Assets:
19.23B
Total Cash:
655.49M


News about "Grifols, S.A."

Grifols, S.A. (NASDAQ:GRFS) Receives Consensus Rating of โ€œHoldโ€ from Analysts

Source from : ETF Daily News - 21 days ago

Shares of Grifols, S.A. (NASDAQ:GRFS โ€“ Get Rating) have been given a consensus rating of โ€œHoldโ€ by the nine brokerages that are currently covering the company, Marketbeat.com reports.See details»


wall-street-pummels-grifols-sa-grfs-after-recent-earnings-report-image

Wall Street Pummels Grifols S.A. (GRFS) After Recent Earnings Report

Source from : newsheater - 6 days ago

Grifols S.A. (NASDAQ:GRFS) went up by 0.31% from its latest closing price compared to the recent 1-year high of $19.07. The companyโ€™s stock price has collected 3.27% of gains in the last five trading ...See details»


Grifols, S.A.: Slightly Adjusting Grifols Fair Value Estimate on FX Fluctuations; Strong Q1, Shares Undervalued

Source from : Yahoo Finance - 16 days ago

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011 ...See details»


Grifols (NASDAQ:GRFS) Downgraded to โ€œSellโ€ at Zacks Investment Research

Source from : ETF Daily News - 22 days ago

According to Zacks, โ€œGrifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy ...See details»


Grifols SA B - Stock Quote GRFPE

Source from : Morningstar%2c Inc. - 3 days ago

There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ...See details»


Grifols SA ADR - Stock Quote GIKLY

Source from : Morningstar%2c Inc. - 6 days ago

There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ...See details»


Grifols SA - ADR - Level III

Source from : U.S. News & World Report - 7 days ago

Investors seeking a good entry point have plenty of options among the best cryptocurrencies to buy now.See details»


Grifols: Long Only

Source from : Seeking Alpha - 15 days ago

After the results, we are more confident on Grifols' ability to navigate the short-term analyst downgrade. Biotest acquisition completed, now it is time to deliver. Given the strong company track ...See details»


Grifols completes the acquisition of Biotest: a strategic and transformational transaction to accelerate growth and innovation

Source from : Stockhouse - 1 month ago

Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this ...See details»


Blood Transfusion Diagnostics Market is experiencing boost at an infinite speed By 2032 | Grifols S.A., Immucor Inc., Ortho Clinical Diagnostics

Source from : xaralite.com - 3 days ago

According to the report by insightSLICE, titled, โ€œBlood Transfusion Diagnostics market: Global Market Share, Trends, Analysis and Forecasts 2022 โ€“ 2032โ€. The report provides a detailed analysis of ...See details»


Biotest AG: Grifols acquires majority of voting rights in Biotest

Source from : Yahoo Finance - 2 days ago

On 12 April 2022, Biotest AG notified that the last outstanding condition for the takeover offer of Grifols S.A. had been fulfilled. Today Grifols SA announced that the voluntary takeover offer ...See details»


GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development

Source from : Associated Press - 6 days ago

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced ...See details»


alpha-1-antitrypsin-deficiency-treatment-market-strong-product-pipeline-is-expected-to-give-impetus-to-growth-says-fortune-business-insights-image

Alpha-1 Antitrypsin Deficiency Treatment Market: Strong Product Pipeline is Expected to Give Impetus to Growth, says Fortune Business Insights

Source from : FOX 40 WICZ TV - 13 days ago

In November 2017, Grifols, S.A., received FDA approval for A1AT Genotyping Test for the diagnosis of alpha-1 antitrypsin deficiency serving as an innovative genetic test which will enable precise and ...See details»


Global Blood Testing Market Forecast to 2029 - Featuring Abbott Laboratories, bioMerieux and Grifols Among Others - ResearchAndMarkets.com

Source from : The Register-Herald - 6 days ago

Companies Mentioned Abbott Laboratories Becton, Dickinson and Company bioMerieux SA Bio-Rad Laboratories Cepheid Corporation Danaher (Beckman Coulter) Grifols, S.A. Novartis International ...See details»